NO994426L - Nye karboksylsyrederivater, deres fremstilling og anvendelse ved behandling av kreft - Google Patents

Nye karboksylsyrederivater, deres fremstilling og anvendelse ved behandling av kreft

Info

Publication number
NO994426L
NO994426L NO994426A NO994426A NO994426L NO 994426 L NO994426 L NO 994426L NO 994426 A NO994426 A NO 994426A NO 994426 A NO994426 A NO 994426A NO 994426 L NO994426 L NO 994426L
Authority
NO
Norway
Prior art keywords
cancer
preparation
treatment
carboxylic acid
acid derivatives
Prior art date
Application number
NO994426A
Other languages
English (en)
Other versions
NO994426D0 (no
Inventor
Cynithia A Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO994426D0 publication Critical patent/NO994426D0/no
Publication of NO994426L publication Critical patent/NO994426L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår en fremgangsmåte for å behandle kreft i et individ, hvor kreften er en svulst hvor endotelin er oppregulert (for eksempel svulster i prostata, lunge, lever, bryst, hjerne, magesekk, kolon, endometrium, testikkel, tyroidkjertelen, hypofysen, blæren, nyrene, pankreas og hjernen) ved at individet administreres en effektiv menge av en forbindelse med formel l eller formel la som beskrevet her.
NO994426A 1997-03-14 1999-09-13 Nye karboksylsyrederivater, deres fremstilling og anvendelse ved behandling av kreft NO994426L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/818,622 US6030975A (en) 1997-03-14 1997-03-14 Carboxylic acid derivatives, their preparation and use in treating cancer
PCT/US1998/004596 WO1998041206A1 (en) 1997-03-14 1998-03-09 Novel carboxylic acid derivatives, their preparation and use in treating cancer

Publications (2)

Publication Number Publication Date
NO994426D0 NO994426D0 (no) 1999-09-13
NO994426L true NO994426L (no) 1999-11-12

Family

ID=25225984

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994426A NO994426L (no) 1997-03-14 1999-09-13 Nye karboksylsyrederivater, deres fremstilling og anvendelse ved behandling av kreft

Country Status (19)

Country Link
US (1) US6030975A (no)
EP (1) EP0969841A1 (no)
JP (1) JP2001517220A (no)
KR (1) KR20000076252A (no)
CN (1) CN1251991A (no)
AU (2) AU744019B2 (no)
BG (1) BG103729A (no)
BR (1) BR9808263A (no)
CA (1) CA2283732A1 (no)
HR (1) HRP980126A2 (no)
HU (1) HUP0002249A3 (no)
ID (1) ID24283A (no)
IL (1) IL131666A0 (no)
NO (1) NO994426L (no)
NZ (1) NZ337557A (no)
PL (1) PL335688A1 (no)
SK (1) SK125299A3 (no)
WO (1) WO1998041206A1 (no)
ZA (1) ZA982136B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
ATE348617T1 (de) * 2000-02-16 2007-01-15 Astellas Pharma Inc Heilmittel gegen durch endothelin verursachte erkrankungen
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
EP2118073A2 (en) 2007-02-02 2009-11-18 Concert Pharmaceuticals Inc. Selective endothelin type-a antagonists
JP5832447B2 (ja) 2009-12-07 2015-12-16 ザ ジョンズ ホプキンス ユニバーシティ ビスアシル化ヒドロキシルアミン誘導体
CN102276536B (zh) * 2011-06-10 2015-04-29 中国科学院化学研究所 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法
CN103709106A (zh) * 2013-12-06 2014-04-09 石家庄博策生物科技有限公司 一种立体选择性制备安立生坦的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
CA2072390A1 (en) * 1991-07-01 1993-01-02 Philip D. Stein Endothelin analogues with alpha-amine substitution at residue 20
CA2072395A1 (en) * 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
WO1993018794A1 (en) * 1992-03-26 1993-09-30 Gensia, Inc. In vivo peptide therapy
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CZ256994A3 (en) * 1992-04-22 1995-02-15 Warner Lambert Co Peptides, process of their preparation and pharmaceutical compositions based thereof
WO1994003483A1 (en) * 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
WO1995005374A1 (en) * 1993-08-18 1995-02-23 Banyu Pharmaceutical Co., Ltd. Fused heteroaromatic cyclopentene derivative having endothelin-antagonist activity
NZ271833A (en) * 1993-08-19 1997-08-22 Warner Lambert Co Substituted 2(5h)-furanone (or thiophenone or pyrrolone) derivatives
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
CA2517691A1 (en) * 1994-08-19 1996-02-29 Abbott Laboratories Endothelin antagonists
WO1996011927A1 (en) * 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
ATE195516T1 (de) * 1995-01-27 2000-09-15 Rhone Poulenc Rorer Ltd Substituierte phenylverbindungen als endothelinantagoniste
CA2168154A1 (en) * 1995-02-06 1996-08-07 Natesan Murugesan Substituted biphenyl sulfonamide endothelin antagonists
DE19614534A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
HRP980126A2 (en) 1998-12-31
HUP0002249A2 (hu) 2001-05-28
BR9808263A (pt) 2000-05-16
WO1998041206A1 (en) 1998-09-24
PL335688A1 (en) 2000-05-08
NO994426D0 (no) 1999-09-13
AU734696B2 (en) 2001-06-21
AU744019B2 (en) 2002-02-14
NZ337557A (en) 2001-08-31
EP0969841A1 (en) 2000-01-12
SK125299A3 (en) 2001-12-03
ID24283A (id) 2000-07-13
BG103729A (en) 2000-04-28
ZA982136B (en) 1999-09-13
KR20000076252A (ko) 2000-12-26
JP2001517220A (ja) 2001-10-02
CN1251991A (zh) 2000-05-03
IL131666A0 (en) 2001-01-28
HUP0002249A3 (en) 2001-11-28
CA2283732A1 (en) 1998-09-24
US6030975A (en) 2000-02-29

Similar Documents

Publication Publication Date Title
De Castro et al. Reduced triphosphopyridinenucleotide requirement for the enzymatic formation of 3-hydroxykynurenine from L-kynurenine
GB0225508D0 (en) Anti-cancer compositions
ES8603455A1 (es) Un metodo para preparar derivados de piperazina
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ZA945604B (en) Tricyclic benzazepepine vasopressin antagonists
NO931153L (no) Vannloeselige camptothecin-analoger fremgangsmaater og metoder
NO20054769L (no) Substituerte fenylalkansyrer
Kazimierczak et al. The effect of zinc ions on selective and nonselective histamine release in vitro
DE60111362D1 (de) Stabilisierte ascorbinsäure-lösungen
ATE116657T1 (de) 7-keto- und 7-hydroxy-androsta-3,5-dien-3- carbonsäure derivate.
WO2006124012A3 (en) Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production
EP1515754A4 (en) BETA-2-GLYCOPROTEIN 1 AS ANGIOGENESEHEMMER
EP0417941A2 (en) Use of a cyanine dye in an antitumor agent
WO2000028020A3 (en) Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
IS5588A (is) Æxliseyðandi miðlar
WO2000004863A3 (en) Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
Stunzi et al. Stability constants of some metal complexes formed by mimosine and related compounds
ES2080726T3 (es) Compuestos aromaticos o heteroaromaticos nitrosustituidos para su utilizacion en el tratamiento del cancer.
Gaweł et al. Influence of zinc hydroaspartate on the anti-inflammatory and gastric activity of ketoprofen in rats
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
MXPA05004845A (es) N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia.
BG103729A (en) New derivatives of carboxylic acids, their preparation and administration for cancer treatment
WO2002074756A3 (de) Urokinase-inhibitoren
ATE355281T1 (de) 1,4,7,10-tetraazacyclododecan-1,4-diessigsäure